Things aren't always as they seem. Take pancreatic cancer, for example. In up to one in 10 cases, researchers have documented a peculiar characteristic. Some of the pancreatic cells appear to have lost their identity. It's as if they forget what they are.
"This is very bizarre. You see pancreatic cancer, which usually somewhat resembles the original organ, losing those features and basically becoming akin to skin or esophagus-;these other very unrelated tissues, " explains former Cold Spring Harbor Laboratory (CSHL) postdoc Diogo Maia-Silva, now at Massachusetts General Hospital. immune cell therapy
For years, researchers have wondered exactly how this deadly disease, known as basal-like pancreatic cancer, works. Now, Maia-Silva and colleagues at CSHL have discovered that a protein called MED12 may play a critical role. While the discovery is notable in and of itself, it also builds on decades of CSHL research.
Twenty-five years ago, CSHL Professor Alea Mills discovered that a protein called p63 is important for the formation of normal basal cells-;small cells in the lower part of the epidermis. Later research from CSHL Professor Christopher Vakoc found that this protein can also cause pancreatic cancer to become basal-like. Exactly how was unclear. Maia-Silva joined Vakoc's lab in 2018, wanting to continue this investigation. Because p63 is notoriously difficult to target with drugs, he wondered which other molecules it might work with to confuse cells.
With his colleagues, he developed a method to screen the entire genome of basal-like cancer cells and rank which genes were most important for maintaining their new identity. In all his tests, MED12 rose to the top. This gene contains instructions for making the MED12 protein, one of about 25 in a complex that regulates gene activity.
That was very unexpected because it's part of this broad complex, but [most] other members of the complex didn't show up. Despite being part of this general machinery of the cell, [MED12] has some unique property that makes it more important for basal biology."
Diogo Maia-Silva, former CSHL postdoc
Further tests showed that MED12 and p63 bind directly to each other. This suggests that each may be required to turn pancreatic cells basal-like. If researchers could one day figure out how to stop this interaction, it's possible they could prevent pancreatic cancer from going basal. However, Maia-Silva is quick to note, this isn't "something that can be easily done." Still, "this is exciting," he adds. "Finding these critical partners is sort of a first step toward blocking the pathway."
It's a new beginning but also yet another exciting conclusion in a string of discoveries at CSHL.
Maia-Silva, D., et al. (2024). Interaction between MED12 and ΔNp63 activates basal identity in pancreatic ductal adenocarcinoma. Nature Genetics. doi.org/10.1038/s41588-024-01790-y
Posted in: Genomics | Medical Research News | Medical Condition News
Tags: Adenocarcinoma, Cancer, Cell, Cold, Drugs, Epidermis, Gene, Genes, Genetics, Genome, Hospital, Laboratory, Pancreatic Cancer, Protein, Research, Skin
Jose Castro-Perez and Chris Lock, SCIEX
In our latest interview, News Medical speaks with SCIEX, a global leader in life science analytical technologies, about their exciting announcements at ASMS, the SCIEX 7500+ System, and how they utilize AI quantitation software to streamline solutions.
In this interview, we speak with Melanie Leveridge, Vice President of Discovery Biology at AstraZeneca and Chair of the Board for ELRIG UK, to discuss her extensive career in the pharmaceutical industry, her role in fostering scientific innovation, and her vision for ELRIG's future.
Revolutionizing Non-Invasive Diagnostics with Plasmion’s SICRIT Breath Analysis.
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.
News-Medical.net - An AZoNetwork Site
Owned and operated by AZoNetwork, © 2000-2024
Your AI Powered Scientific Assistant
Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.
A few things you need to know before we start. Please read and accept to continue.
Azthena may occasionally provide inaccurate responses. Read the full terms.
While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.
Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.
Please do not ask questions that use sensitive or confidential information.
prostatectomy Read the full Terms & Conditions.